Challenging Times for European Biotech IPOs

Through the first week of May, 2005, five biotechs listed on Europe's main markets. Like their counterparts in the US, these companies have had to deal with difficult public markets and have on the whole raised much less money than they originally intended.

European private investors are faring no better than their US counterparts when it comes to IPOs in 2005. Both sides of the Atlantic have been plagued by problematic public markets that have resulted in public offerings at or below estimated pricing ranges and difficult aftermarket environments. (See Exhibit 1.) So far this year five firms have hit Europe's main markets: Ardana Bioscience Ltd. on the London Stock Exchange [See Deal], Intercell AG in Vienna [See Deal], Paion AG in Frankfurt [See Deal], Arpida Ltd. on the Swiss Exchange [See Deal], and, most recently as of START-UP press time, Galapagos Genomics NV in Amsterdam and Brussels [See Deal]. Much like in the US, others including Scotland's Cyclacel Ltd. , have gotten cold feet and pulled their offerings [See Deal].

While US companies have traditionally enjoyed public market support unavailable to European companies, those days are seemingly gone. The wave...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

BREAKING NEWS: Merck & Co. Leaps Into COPD Space With $10bn Verona Buy

 
• By 

The UK firm's chronic obstructive pulmonary drug Ohtuvayre has been enjoying a stellar launch.

Wave of Biopharma Licensing Deals in India: ‘The Model Is Working’

 

From vonoprazan and inclisiran to nirsevimab, big pharma has licensed several products to Indian firms as have other biopharma players. Experts discuss the intricacies of such licensing deals amid signs of more action in store and whether geopolitics could dull partnering with Chinese firms.

Novartis Secures Approval For First Malaria Therapy for Babies

 
• By 

Coartem Baby to be rolled out in eight African countries in the autumn.

KalVista’s Delayed FDA Approval In HAE Comes Through

 
• By 

KalVista’s Ekterly obtains US approval as the first oral, on-demand therapy for hereditary angioedema. It will compete with established injectables.

More from Business

Actithera Raises $75m To Enter Competitive FAP-Targeting Radioligand Field

 

While companies such as Eli Lilly and Roche have faced setbacks to their fibroblast activation protein-targeting oncology therapies, Actithera believes its radiopharmaceuticals platform will prove more successful.

Concentra Picks Up Cargo In Latest Troubled Biotech Buyout

 

The Kevin Tang-led firm will pay $4.38 per share for Cargo, which laid off most of its workforce following the failure of a Phase II CAR-T trial.

Venture Funding Plummets In Q2 As Mega-Rounds Falter

 
• By 

Evaluate’s second quarter data show that VC rounds of $100m or more totaled $2.36bn, down from $5.25bn in Q2 of 2024. Overall, the Q2 total dropped year-over-year to $4.92bn from $7.95bn.